Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease

References

• Cui G, Fan Q, Li Z, et al. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: current and novel biomarkers. EBioMedicine. 2021 Apr;66:103329. doi: 10.1016/j.ebiom.2021.103329
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. doi: 10.3389/fphar.2019.00279
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Companies. REMICADE® (infliximab). Prescribing information. Janssen Pharmaceutical Companies; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf
   Google Scholar
• US Food and Drug Administration. Biosimilar product information 2021 [ updated 2021 Sept 20; cited 2021 Oct 11]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
   Google Scholar
• Generics and Biosimilars Initiative. FDA approves infliximab biosimilar inflectra. GaBi Online; 2016 [cited 2022 Sep 23]. Available from: https://www.gabionline.net/biosimilars/news/FDA-approves-infliximab-biosimilar-Inflectra
   Google Scholar
• European Medicines Agency. Remsima: EPAR. Product information. European Medicines Agency; 2013 [cited 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima
   Google Scholar
• Generics and Biosimilars Initiative. FDA approves biosimilar infliximab Renflexis. GaBi Online; 2017 [ updated 2017 May 05;cited 2022 Sep 23]. updated 2017 May 05 https://www.gabionline.net/biosimilars/news/FDA-approves-biosimilar-infliximab-Renflexis
   Google Scholar
• European Medicines Agency. Flixabi: EPAR. product information. European Medicines Agency; 2016. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi
   Google Scholar
• Generics and Biosimilars Initiative. FDA approves biosimilar infliximab Ixifi. GaBi Online; 2018. Available from: https://www.gabionline.net/biosimilars/news/FDA-approves-biosimilar-infliximab-Ixifi
   Google Scholar
• European Medicines Agency. Zessly: EPAR. product information. European Medicines Agency; 2018 [cited 2023 Mar 28]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zessly
   Google Scholar
• Haifer C, Srinivasan A, An YK, et al. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Med J Aust. 2021 Feb;214(3):128–133. doi: 10.5694/mja2.50824
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Biosimilar development, review, and approval 2017 [ updated 2017 Oct 20;cited 2022 Sep 23]. updated 2017 Oct 20 https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval
   Google Scholar
• Troein P, Newton M, Scott K, et al. The impact of biosimilar competition in Europe. IQVIA white paper. 2021. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf
   Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017 Dec;31(6):533–544. doi: 10.1007/s40259-017-0252-3
   PubMed Web of Science ®Google Scholar
• Chen AJ, Ribero R, Van Nuys K. Provider differences in biosimilar uptake in the filgrastim market. Am J Manag Care. 2020 May;26(5):208–213.
   PubMed Web of Science ®Google Scholar
• Edgar BS, Cheifetz AS, Helfgott SM, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021 Aug;27(8):1129–1135. doi: 10.18553/jmcp.2021.27.8.1129
   PubMed Web of Science ®Google Scholar
• Oskouei ST, Kusmierczyk AR. Biosimilar uptake: the importance of healthcare provider education. Pharmaceut Med. 2021 Jul;35(4):215–224. doi: 10.1007/s40290-021-00396-7
   PubMed Web of Science ®Google Scholar
• Baer Ii WH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014 May 7;7(5):530–544. doi: 10.3390/ph7050530
   PubMedGoogle Scholar
• Lammers P, Criscitiello C, Curigliano G, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014 Sep 17;7(9):943–953. doi: 10.3390/ph7090943
   PubMedGoogle Scholar
• Socinski MA, Curigliano G, Jacobs I, et al. Clinical considerations for the development of biosimilars in oncology. MAbs. 2015;7(2):286–293. doi: 10.1080/19420862.2015.1008346
   PubMed Web of Science ®Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016 Aug;27(8):1423–1443. doi: 10.1093/annonc/mdw213
   PubMed Web of Science ®Google Scholar
• Monk BJ, Lammers PE, Cartwright T, et al. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. Pharmaceuticals (Basel). 2017 Jan 28;10(1):19. doi: 10.3390/ph10010019
   PubMedGoogle Scholar
• Lepelaars LRA, Renda F, Pani L, et al. Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. Br J Clin Pharmacol. 2018 Apr;84(4):738–763. doi: 10.1111/bcp.13454
   PubMed Web of Science ®Google Scholar
• Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26(4):299–302. doi: 10.3109/09546634.2015.1054782
   PubMed Web of Science ®Google Scholar
• Leonard E, Wascovich M, Oskouei S, et al. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019 Jan;25(1):102–112. doi: 10.18553/jmcp.2019.25.1.102
   PubMed Web of Science ®Google Scholar
• Halimi V, Daci A, Ancevska Netkovska K, et al. Clinical and regulatory concerns of biosimilars: a review of literature. Int J Environ Res Public Health. 2020 Aug 11;17(16):5800. doi: 10.3390/ijerph17165800
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019 Jan;49(1):31–40. doi: 10.1111/apt.14997
   PubMed Web of Science ®Google Scholar
• Mysler E, Azevedo VF, Danese S, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021 Nov;81(16):1859–1879. doi: 10.1007/s40265-021-01610-1
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000 [cited 2023 Mar 28]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• National Heart Lung and Blood Institute. Study quality assessment tools 2021 [ updated 2023 January 17;cited 2023 Mar 28]. updated 2023 January 17 https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
   Google Scholar
• Binkhorst L, Sobels A, Stuyt R, et al. Short article: switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2018 Jul;30(7):699–703. doi: 10.1097/MEG.0000000000001113
   PubMed Web of Science ®Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018 May;74(5):655–661. doi: 10.1007/s00228-018-2418-4
   PubMed Web of Science ®Google Scholar
• Hanzel J, Jansen JM, Ter Steege RWF, et al. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study. Inflamm Bowel Dis. 2021 May 20;28(4):495–501. doi: 10.1093/ibd/izab099
   Web of Science ®Google Scholar
• Mahmmod S, Schultheiss JPD, van Bodegraven AA, et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021 Nov 15;27(12):1954–1962. doi: 10.1093/ibd/izaa364
   PubMed Web of Science ®Google Scholar
• Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018 Feb;47(3):356–363. doi: 10.1111/apt.14453
   PubMed Web of Science ®Google Scholar
• Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016 Nov;10(11):1287–1293. doi: 10.1093/ecco-jcc/jjw087
   PubMed Web of Science ®Google Scholar
• Smits LJT, Grelack A, Derikx L, et al. Long-term clinical outcomes after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2017 Nov;62(11):3117–3122. doi: 10.1007/s10620-017-4661-4
   PubMed Web of Science ®Google Scholar
• Smits LJT, van Esch AAJ, Derikx L, et al. Drug survival and immunogenicity after switching from Remicade to biosimilar CT-P13 in inflammatory bowel disease patients: two-year follow-up of a prospective observational cohort study. Inflamm Bowel Dis. 2019 Jan 1;25(1):172–179. doi: 10.1093/ibd/izy227
   PubMed Web of Science ®Google Scholar
• Mahmmod S, Schultheiss JPD, Tan T, et al. P326 reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar. J Crohns Colitis. 2020;14(Suppl 1):S316–S317. doi: 10.1093/ecco-jcc/jjz203.455
   PubMedGoogle Scholar
• Bhat S, Altajar S, Shankar D, et al. Process and clinical outcomes of a biosimilar adoption program with infliximab-Dyyb. J Manag Care Spec Pharm. 2020 Apr;26(4):410–416. doi: 10.18553/jmcp.2020.26.4.410
   PubMed Web of Science ®Google Scholar
• Ho SL, Niu F, Pola S, et al. Effectiveness of switching from reference product infliximab to infliximab-dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: a retrospective, propensity score-matched, non-inferiority cohort study. BioDrugs. 2020 Jun;34(3):395–404. doi: 10.1007/s40259-020-00409-y
   PubMed Web of Science ®Google Scholar
• Khan N, Patel D, Pernes T, et al. The efficacy and safety of switching from originator infliximab to single or double switch biosimilar among a nationwide cohort of inflammatory bowel disease patients. Crohns Colitis 360. 2021;3(2):otab022. doi: 10.1093/crocol/otab022
   PubMedGoogle Scholar
• Mehta SA, Ritter TE, Fernandes CC, et al. S837 payor-mandated non-medical switching from infliximab to biosimilar creates dosing delays. Am J Gastroenterol. 2021;116(1):S388. doi: 10.14309/01.ajg.0000776880.16345.04
   Google Scholar
• Padival R, Qayyum F, Lee JA, et al. Fr525 biosimilar switch in a large quaternary care American medical institution does not result in worsening of inflammatory bowel disease activity. Gastroenterology. 2021;160(6):S346–7. doi: 10.1016/S0016-5085(21)01546-8
   PubMed Web of Science ®Google Scholar
• Padival R, Heis F, Lee JA, et al. S0820 real world comparison of bio-originator infliximab vs the biosimilar infliximab-abda in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2020;115(1):S421–S422. doi: 10.14309/01.ajg.0000705328.61690.cb
   Google Scholar
• Pernes T, Patel M, Khan N. S0792 the safety of switching from originator infliximab or biosimilar CT-P13 to SB2 among a nationwide cohort of inflammatory bowel disease patients. Am J Gastroenterol. 2020;115(1):S405. doi: 10.14309/01.ajg.0000705216.13543.4d
   Google Scholar
• Yoo T, Zhornitskiy A, Fung B, et al. S0858 assessing the efficacy and safety of a transition from infliximab to infliximab biosimilar in the management of IBD in a safety net population. Am J Gastroenterol. 2020 Oct 01;115:S443. doi: 10.14309/01.ajg.0000705480.65270.c6
   Web of Science ®Google Scholar
• Kim NH, Lee JH, Hong SN, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2019 Sep;34(9):1523–1532. doi: 10.1111/jgh.14645
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kobayashi T, Nishikawa K, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019 Oct;17(4):504–515. doi: 10.5217/ir.2019.00030
   PubMed Web of Science ®Google Scholar
• Kang B, Lee Y, Lee K, et al. Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study. Inflamm Bowel Dis. 2018 Feb 15;24(3):607–616. doi: 10.1093/ibd/izx047
   PubMed Web of Science ®Google Scholar
• Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015 Apr;60(4):951–956. doi: 10.1007/s10620-014-3392-z
   PubMed Web of Science ®Google Scholar
• Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44. doi: 10.1586/17474124.2015.1091309
   PubMedGoogle Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015 Dec;30(12):1705–1712. doi: 10.1111/jgh.12997
   PubMed Web of Science ®Google Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019 Apr 27;393(10182):1699–1707. doi: 10.1016/S0140-6736(18)32196-2
   PubMed Web of Science ®Google Scholar
• Cheon J, Kang H, Lee S, et al. P358 an observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn’s disease or ulcerative colitis. J Crohns Colitis. 2021 May 27;15(Supplement_1):S378–S379. doi: 10.1093/ecco-jcc/jjab076.482
   Google Scholar
• Cheon JH, Nah S, Kang HW, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness. Adv Ther. 2021 Aug;38(8):4366–4387. doi: 10.1007/s12325-021-01834-3
   PubMed Web of Science ®Google Scholar
• Abraham B, Eksteen B, Nedd K, et al. Impact of infliximab-dyyb (infliximab biosimilar) on clinical and patient-reported outcomes: 1-year follow-up results from an observational real-world study among patients with inflammatory bowel disease in the US and Canada (the ONWARD study). Adv Ther. 2022 May;39(5):2109–2127. doi: 10.1007/s12325-022-02104-6
   PubMed Web of Science ®Google Scholar
• Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021 Apr;53(8):887–899. doi: 10.1111/apt.16312
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Viola A, et al. The SPOSIB SB2 Sicilian cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches. Inflamm Bowel Dis. 2021 Jan 19;27(2):182–189. doi: 10.1093/ibd/izaa036
   PubMed Web of Science ®Google Scholar
• Mazza S, Piazza O, Sed N, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): a multicenter cohort study. Clin Transl Sci. 2022 Jan;15(1):172–181. doi: 10.1111/cts.13131
   PubMed Web of Science ®Google Scholar
• Lovero R, Losurdo G, La Fortezza RF, et al. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):201–207. doi: 10.1097/MEG.0000000000001988
   PubMed Web of Science ®Google Scholar
• Luber RP, O’Neill R, Singh S, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021 Sep;54(5):678–688. doi: 10.1111/apt.16497
   PubMed Web of Science ®Google Scholar
• Siakavellas SI, Barrett RA, Plevris N, et al. 610 both single and multiple switching between infliximab biosimilars can be safe and effective in inflammatory bowel disease (IBD): real world outcomes from the Edinburgh IBD unit. Gastroenterology. 2021;160(6):S120. doi: 10.1016/S0016-5085(21)01042-8
   Web of Science ®Google Scholar
• Ilias A, Szanto K, Gonczi L, et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to remicade. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2506–2513. doi: 10.1016/j.cgh.2018.12.036
   PubMed Web of Science ®Google Scholar
• Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019 Jun;285(6):653–669. doi: 10.1111/joim.12880
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Goll GL, Sexton J, et al. Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials. BioDrugs. 2020 Oct;34(5):681–694. doi: 10.1007/s40259-020-00438-7
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet. 2017 Jun 10;389(10086):2304–2316. doi: 10.1016/S0140-6736(17)30068-5
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Fiorino G, Variola A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019 Feb 21;25(3):568–579. doi: 10.1093/ibd/izy264
   PubMed Web of Science ®Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017 Feb;23(2):233–243. doi: 10.1097/MIB.0000000000000995
   PubMed Web of Science ®Google Scholar
• Tursi A, Allegretta L, Chiri S, et al. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real-life experience in IBD primary centers. Minerva Gastroenterol Dietol. 2017 Dec;63(4):313–318. doi: 10.23736/S1121-421X.17.02402-3
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Faggiani R, et al. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol. 2019 Jul;32(4):392–399. doi: 10.20524/aog.2019.0377
   PubMed Web of Science ®Google Scholar
• Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol & Hepatol. 2017;29(11):1290–1295. doi: 10.1097/MEG.0000000000000953
   PubMed Web of Science ®Google Scholar
• Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci. 2017 May 01;62(5):1305–1312. doi: 10.1007/s10620-017-4511-4
   PubMed Web of Science ®Google Scholar
• Avouac J, Moltó A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr;47(5):741–748. doi: 10.1016/j.semarthrit.2017.10.002
   PubMed Web of Science ®Google Scholar
• Bergqvist V, Kadivar M, Molin D, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818801244. doi: 10.1177/1756284818801244
   Web of Science ®Google Scholar
• Bouhnik Y, Fautrel B, Desjeux G, et al. PERFUSE: a French non-interventional cohort study of infliximab-naive and transitioned patients receiving infliximab biosimilar SB2; an interim analysis. J Crohns Colitis. 2020;14(Suppl 1):S529. doi: 10.1093/ecco-jcc/jjz203.765
   Google Scholar
• Bouhnik Y, Fautrel B, Beaugerie L, et al. PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis. Therap Adv Gastroenterol. 2023;16:17562848221145654. doi: 10.1177/17562848221145654
   Web of Science ®Google Scholar
• Bronswijk M, Moens A, Lenfant M, et al. Evaluating efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar CT-P13: experience from a large tertiary referral center. Inflamm Bowel Dis. 2020 Mar 4;26(4):628–634. doi: 10.1093/ibd/izz167
   PubMed Web of Science ®Google Scholar
• Buer LC, Moum BA, Cvancarova M, et al. Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017 Mar 1;11(3):297–304. doi: 10.1093/ecco-jcc/jjw166
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Guerra Veloz MF, et al. Effectiveness and safety of the switch from Remicade® to CT-P13 in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Oct 28;13(11):1380–1386. doi: 10.1093/ecco-jcc/jjz070
   PubMed Web of Science ®Google Scholar
• Eberl A, Huoponen S, Pahikkala T, et al. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scand J Gastroenterol. 2017 Dec;52(12):1348–1353. doi: 10.1080/00365521.2017.1369561
   PubMed Web of Science ®Google Scholar
• Fischer S, Cohnen S, Klenske E, et al. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therap Adv Gastroenterol. 2021;14:1756284820982802. doi: 10.1177/1756284820982802
   Web of Science ®Google Scholar
• Fischer S, Mesfin S, Klenske E, et al. P548 efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: a long-term observational, prospective cohort study. J Crohn’s And Colitis. 2020;14(Supplement_1):S466–S467. doi: 10.1093/ecco-jcc/jjz203.676
   Google Scholar
• Gervais L, McLean LL, Wilson ML, et al. Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful. J Pediatr Gastroenterol Nutr. 2018 Dec;67(6):745–748. doi: 10.1097/MPG.0000000000002091
   PubMed Web of Science ®Google Scholar
• Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol. 2019;12:1756284819858052. doi: 10.1177/1756284819858052
   Web of Science ®Google Scholar
• Guerrero Puente L, Iglesias Flores E, Benitez JM, et al. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission. Gastroenterol Hepatol. 2017 Nov;40(9):595–604. doi: 10.1016/j.gastrohep.2017.07.005
   PubMed Web of Science ®Google Scholar
• Hlavaty T, Krajcovicova A, Sturdik I, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases – a one-year, single-centre retrospective study. Gastroenterol Hepatol. 2016;70(1):27–36. doi: 10.14735/amgh201627
   Google Scholar
• Hoivik ML, Buer LCT, Cvancarova M, et al. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018 Jun;53(6):692–699. doi: 10.1080/00365521.2018.1463391
   PubMed Web of Science ®Google Scholar
• Huguet JM, Cortés X, Bosca-Watts MM, et al. Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease. World J Clin Cases. 2021 Dec 26;9(36):11285–11299. doi: 10.12998/wjcc.v9.i36.11285
   PubMed Web of Science ®Google Scholar
• Huoponen S, Eberl A, Räsänen P, et al. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore). 2020 Jan;99(2):e18723. doi: 10.1097/MD.0000000000018723
   PubMed Web of Science ®Google Scholar
• Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (remsima) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017;35(1–2):91–100. doi: 10.1159/000453343
   PubMed Web of Science ®Google Scholar
• Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022 Apr;38(4):613–627. doi: 10.1080/03007995.2022.2037846
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Viola A, et al. P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2. J Crohn's Colitis. 2020;14(Suppl 1):S387–S388. doi: 10.1093/ecco-jcc/jjz203.554
   Google Scholar
• Martín-Gutiérrez N, Sanchez-Hernandez JG, Rebollo N, et al. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. Eur J Hosp Pharm. 2020 Oct 28;29(4):222–227. doi: 10.1136/ejhpharm-2020-002410
   PubMedGoogle Scholar
• Massimi D, Barberio B, Bertani L, et al. Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study. Therap Adv Gastroenterol. 2021 Jan 01;14:17562848211023384. doi: 10.1177/17562848211023384
   Web of Science ®Google Scholar
• Mazza S, Fasci A, Casini V, et al. Mo1872 safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): a multicentre study. Gastroenterology. 2020;158(6):S957. doi: 10.1016/S0016-5085(20)33071-7
   Web of Science ®Google Scholar
• Nascimento C, Revés J, Morão B, et al. P555 outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease. J Crohn’s And Colitis. 2021;15(Supplement_1):S520–S521. doi: 10.1093/ecco-jcc/jjab076.676
   Google Scholar
• Petitdidier N, Tannoury J, De’angelis N, et al. Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Dig Liver Dis. 2019 Dec;51(12):1652–1660. doi: 10.1016/j.dld.2019.08.020
   PubMedGoogle Scholar
• Plevris N, Jones GR, Jenkinson PW, et al. Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes. Dig Dis Sci. 2019 Jun;64(6):1660–1667. doi: 10.1007/s10620-018-5406-8
   PubMed Web of Science ®Google Scholar
• Privitera G, Pugliese D, Tolusso B, et al. Sa1877 effectiveness, safety and immunogenicity of switching from originator infliximab to biosimilar infliximab (CT-P13) in a large cohort of IBD patients. Gastroenterology. 2020;158(6):S462. doi: 10.1016/S0016-5085(20)31836-9
   Web of Science ®Google Scholar
• Pugliese D, Guidi L, Privitera G, et al. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. Expert Opin Biol Ther. 2021 Jan;21(1):97–104. doi: 10.1080/14712598.2020.1839045
   PubMed Web of Science ®Google Scholar
• Ratnakumaran R, To N, Gracie DJ, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018 Jun;53(6):700–707. doi: 10.1080/00365521.2018.1464203
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017 Jun 1;11(6):690–696. doi: 10.1093/ecco-jcc/jjw216
   PubMed Web of Science ®Google Scholar
• Sieczkowska J, Jarzebicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016 Feb;10(2):127–132. doi: 10.1093/ecco-jcc/jjv233
   PubMed Web of Science ®Google Scholar
• Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7
   PubMed Web of Science ®Google Scholar
• van Hoeve K, Dreesen E, Hoffman I, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. Ther Drug Monit. 2019 Jun;41(3):317–324. doi: 10.1097/FTD.0000000000000601
   PubMed Web of Science ®Google Scholar
• Guiotto C, Italia A, Lavagna A, et al. Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. Dig Liver Dis. 2019 Aug;51(8):1117–1122. doi: 10.1016/j.dld.2019.05.018
   PubMedGoogle Scholar
• Hellstrom PM, Gemmen E, Ward HA, et al. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational project NORTH study. Scand J Gastroenterol. 2022 Dec;57(12):1435–1442. doi: 10.1080/00365521.2022.2090275
   PubMed Web of Science ®Google Scholar
• Privitera G, Pugliese D, Onali S, et al. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev. 2021 Jun;20(6):102832. doi: 10.1016/j.autrev.2021.102832
   PubMed Web of Science ®Google Scholar
• Fitzgerald T, Melsheimer R, Lafeuille MH, et al. Switching and discontinuation patterns among patients stable on originator infliximab who switched to an infliximab Biosimilar or remained on originator infliximab. Biologics. 2021;15:1–15. doi: 10.2147/BTT.S285610
   PubMed Web of Science ®Google Scholar
• Abraham BP, Hunter TM, Naegeli AN, et al. S0724 Characteristics of Crohn’s disease patients in the Corrona inflammatory bowel disease registry on biological or conventional therapy differ by disease duration. Am J Gastroenterol. 2020;115(1):S363–4. doi: 10.14309/01.ajg.0000704944.80928.b2
   Google Scholar
• Padival R, Qayyum F, Lee JA, et al. Fr525 biosimilar switch in a large quaternary care American medical institution does not result in worsening of inflammatory bowel disease activity. Gastroenterology. 2021;160(6):S346–S347. doi: 10.1016/S0016-5085(21)01546-8
   PubMed Web of Science ®Google Scholar
• Guerra Veloz MF, Arguelles-Arias F, Castro Laria L, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018 Dec 14;24(46):5288–5296. doi: 10.3748/wjg.v24.i46.5288
   PubMed Web of Science ®Google Scholar
• Guerra Veloz MF, Vazquez Moron JM, Belvis Jimenez M, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enferm Dig. 2018 Sep;110(9):564–570. doi: 10.17235/reed.2018.5368/2017
   PubMed Web of Science ®Google Scholar
• Abraham BP, Eksteen B, Nedd K, et al. S0725 impact of infliximab-dyyb (infliximab biosimilar) on clinical and patient-reported outcomes: 1-year follow-up results from an observational real world study among patients with inflammatory bowel disease (ONWARD study). Am J Gastroenterol. 2020;115(1):S364. doi: 10.14309/01.ajg.0000704948.53832.1a
   Google Scholar
• Luber RP, O’Neill R, Singh S, et al. Sa1882 switching infliximab biosimilar: no adverse impact on IBD control or drug levels with first or second switch. Gastroenterology. 2020;158(6):S464. doi: 10.1016/S0016-5085(20)31841-2
   Web of Science ®Google Scholar
• Hlavaty T, Krajcovicova A, Sturdik I, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. J Crohns & Colitis. 2016;10(suppl_1):S433. doi: 10.1093/ecco-jcc/jjw019.774
   Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr., et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018 Sep;179(3):623–631. doi: 10.1111/bjd.16890
   PubMed Web of Science ®Google Scholar
• Menter A, Cohen S, Kay J, et al. Switching between adalimumab reference product and bi 695501 in patients with chronic plaque psoriasis (VOLTAIRE-X): a randomized controlled trial. Am J Clin Dermatol. 2022 Sep;23(5):719–728. doi: 10.1007/s40257-022-00708-w
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kay R, Reznichenko N, et al. Assessing the interchangeability of AVT02 and Humira((R)) in participants with Moderate‑to‑Severe chronic plaque psoriasis: pharmacokinetics, efficacy, safety, and immunogenicity results from a multicenter, double-blind, randomized, parallel-group study. BioDrugs. 2023 Jul;37(4):551–567. doi: 10.1007/s40259-023-00600-x
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Saikali W, Lakhanpal S, et al. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study. Lancet Rheumatol. 2023;5(9):E532–E541. doi: 10.1016/S2665-9913(23)00161-3
   PubMedGoogle Scholar
• Fiorino G, Ruiz-Arguello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):601–606. doi: 10.1093/ibd/izx086
   PubMed Web of Science ®Google Scholar